NAS:XTLB (Israel)  
XTL Biopharmaceuticals Ltd logo

XTL Biopharmaceuticals Ltd

$ 1.13 -0.0858 (-7.03%) 08:08 PM EST
P/E:
38.34
P/B:
1.05
Market Cap:
$ 6.33M
Enterprise V:
$ 1.53M
Volume:
68.17K
Avg Vol (2M):
9.77K
Also Trade In:
Volume:
68.17K
Market Cap $:
6.33M
PE Ratio:
38.34
Avg Vol (2-Month):
9.77K
Enterprise Value $:
1.53M
PB Ratio:
1.05
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE). hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.97
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -6.3
3-Year Book Growth Rate -11.2
Name Current Vs Industry Vs History
5-Day RSI 11.86
9-Day RSI 22.51
14-Day RSI 28.96
6-1 Month Momentum % -35.42
12-1 Month Momentum % -62.83

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 31.26
Quick Ratio 31.26
Cash Ratio 29.98

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -2

Financials

XTLB's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:XTLB

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) 0.076
Beta 0.97
Volatility % 24.97
14-Day RSI 28.96
14-Day ATR ($) 0.10991
20-Day SMA ($) 1.390205
12-1 Month Momentum % -62.83
52-Week Range ($) 0.8503 - 4.5799
Shares Outstanding (Mil) 5.45

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

XTL Biopharmaceuticals Ltd Filings

Document Form Filing Date
No Filing Data

XTL Biopharmaceuticals Ltd Analysis

Share your research

Headlines

See More
No news.